DexCom, Inc. (NASDAQ:DXCM) insider Andrew K. Balo sold 9,107 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $151.56, for a total transaction of $1,380,256.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Andrew K. Balo also recently made the following trade(s):
- On Tuesday, September 3rd, Andrew K. Balo sold 37 shares of DexCom stock. The shares were sold at an average price of $170.00, for a total transaction of $6,290.00.
Shares of NASDAQ DXCM traded up $1.46 during mid-day trading on Wednesday, reaching $146.70. 911,812 shares of the company were exchanged, compared to its average volume of 1,200,108. The company’s 50-day simple moving average is $160.01 and its 200-day simple moving average is $139.33. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56. The stock has a market capitalization of $13.26 billion, a P/E ratio of 489.00 and a beta of 0.72. DexCom, Inc. has a twelve month low of $105.05 and a twelve month high of $178.45.
DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.01 by $0.07. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business had revenue of $336.40 million during the quarter, compared to the consensus estimate of $304.40 million. During the same quarter in the previous year, the firm posted ($0.10) EPS. DexCom’s revenue was up 38.7% compared to the same quarter last year. As a group, equities research analysts expect that DexCom, Inc. will post 0.94 EPS for the current year.
A number of hedge funds have recently modified their holdings of DXCM. Gradient Investments LLC acquired a new stake in shares of DexCom during the second quarter worth $25,000. Virtus ETF Advisers LLC bought a new stake in shares of DexCom in the second quarter valued at about $29,000. CSat Investment Advisory L.P. bought a new stake in shares of DexCom in the second quarter valued at about $31,000. Steward Partners Investment Advisory LLC acquired a new position in shares of DexCom in the second quarter valued at about $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in shares of DexCom in the second quarter valued at about $37,000. Hedge funds and other institutional investors own 96.79% of the company’s stock.
A number of brokerages have recently commented on DXCM. TheStreet raised shares of DexCom from a “d+” rating to a “c” rating in a research report on Friday, June 28th. Canaccord Genuity upped their target price on shares of DexCom from $160.00 to $185.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Piper Jaffray Companies raised their target price on shares of DexCom from $173.00 to $182.00 and gave the company a “positive” rating in a research note on Wednesday, July 31st. Zacks Investment Research downgraded shares of DexCom from a “buy” rating to a “hold” rating and set a $163.00 target price for the company. in a research note on Monday, August 12th. Finally, ValuEngine cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 1st. Six research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus price target of $168.44.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: How to invest in blue-chip stocks
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.